entertainment -WSS

entertainment

author：knowledge 2025-09-29 16:25:33 - browse：46

STAT's Megan Molteni speaks with Feng Zhang in New York on March 21, 2024 — Scientist Feng Zhang, right, is interviewed by reporter Megan Molteni at STAT's Breakthrough Summit East. STAT

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders.

But now, a decade later, Editas is seen as lagging behind its peers. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, won the race to get the first CRISPR-based medicine across the finish line. Intellia Therapeutics was the first to show that CRISPR editing could be performed inside the body. Editas, meanwhile, has seen a revolving door among its executives.

So what happened?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

WSS

What we owe ALS patients — and why one company fell short

Some top drug companies are starting to take action on climate

Biden announces an advanced cancer research initiative

Study points to new risk in gene therapy death of Terry Horgan

An outrageous hospital charge: I paid $710 for an hour of babysitting

The Karikó problem: Lessons for funding basic research

focus

entertainment

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Continuity nursing helped my family in our darkest PICU moments

Hospitals, health systems can help patients avoid medical debt

DIEP, the 'gold standard' of breast reconstruction, is under threat

The biotech scorecard for Q4: 16 stock

Anesthesiologist group: stop taking Ozempic before surgery

CDC picks Alphabet's Verily for wasterwater surveillance contract

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'The boss' wants server deleted: New allegations emerge in Trump indictment

focus

Will an HIV vaccine ever be a reality?

Stoke drug shows lower activity against childhood epilepsy

RSV injection headlines need to be accurate for good uptake

IVG is promising — but it won’t replace IVF quite yet

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

knowledge

hotspot

leisure time

hotspot